[Cellular restriction factors that inhibit human immunodeficiency virus replication: new strategies in antiretroviral therapy]. 2014

Yazmín Moreno-Valencia, and Loana Xonaí Alvarez-García, and Joel Armando Vázquez-Pérez

Human immunodeficiency virus requires receptors and cellular factors in target cells in order to complete a successful replication. Conversely, host cells express different proteins like TRIM5a, Tetherin BST-2, as well as cytidine deaminase proteins (APOBEC3) to suppress viral replication. These proteins, known as cellular restriction factors, provide an initial defense against infection as components of the innate immune response. The best characterized restriction factor is the cytidine deaminase APOBEC3G that has been shown to have an important role in HIV pathogenesis. Here, we review the current knowledge of host restriction factors, focusing on APOBEC3G, and possible therapeutic strategies against HIV infection.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D003564 Cytidine Deaminase An enzyme that catalyzes the deamination of cytidine, forming uridine. EC 3.5.4.5. Cytidine Aminohydrolase,Aminohydrolase, Cytidine,Deaminase, Cytidine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071480 APOBEC-3G Deaminase An APOBEC deaminase that functions as an inhibitor of RETROVIRIDAE replication and inhibits the mobility of RETROTRANSPOSONS via deaminase-dependent and independent mechanisms. It is selective for SINGLE-STRANDED DNA and does not deaminate double-stranded DNA or single or DOUBLE-STRANDED RNA. It exhibits potent antiviral activity against VIF PROTEIN deficient HIV-1 through the creation of hypermutations in the VIRAL DNA. It also has anti-viral activity against SIMIAN IMMUNODEFICIENCY VIRUSES and HEPATITIS B VIRUS. APOBEC-3G Protein,APOBEC-3G dC-dU Editing Enzyme,APOBEC-Related Cytidine Deaminase,APOBEC-Related Protein,APOBEC3G Deaminase,APOBEC3G Protein,CEM15 Protein,APOBEC 3G Deaminase,APOBEC 3G Protein,APOBEC 3G dC dU Editing Enzyme,APOBEC Related Cytidine Deaminase,APOBEC Related Protein,Cytidine Deaminase, APOBEC-Related,Deaminase, APOBEC-3G,Deaminase, APOBEC3G
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Yazmín Moreno-Valencia, and Loana Xonaí Alvarez-García, and Joel Armando Vázquez-Pérez
September 2009, BMC medicine,
Yazmín Moreno-Valencia, and Loana Xonaí Alvarez-García, and Joel Armando Vázquez-Pérez
January 2011, Bioorganic & medicinal chemistry letters,
Yazmín Moreno-Valencia, and Loana Xonaí Alvarez-García, and Joel Armando Vázquez-Pérez
May 2003, Antiviral research,
Yazmín Moreno-Valencia, and Loana Xonaí Alvarez-García, and Joel Armando Vázquez-Pérez
October 2011, Viruses,
Yazmín Moreno-Valencia, and Loana Xonaí Alvarez-García, and Joel Armando Vázquez-Pérez
July 1999, Nature medicine,
Yazmín Moreno-Valencia, and Loana Xonaí Alvarez-García, and Joel Armando Vázquez-Pérez
February 1999, Pharmacotherapy,
Yazmín Moreno-Valencia, and Loana Xonaí Alvarez-García, and Joel Armando Vázquez-Pérez
September 2008, Antimicrobial agents and chemotherapy,
Yazmín Moreno-Valencia, and Loana Xonaí Alvarez-García, and Joel Armando Vázquez-Pérez
January 1990, AIDS clinical review,
Yazmín Moreno-Valencia, and Loana Xonaí Alvarez-García, and Joel Armando Vázquez-Pérez
September 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
Yazmín Moreno-Valencia, and Loana Xonaí Alvarez-García, and Joel Armando Vázquez-Pérez
November 2012, The Journal of biological chemistry,
Copied contents to your clipboard!